How is Microsatellite Instability (MSI) evaluated in molecular diagnostic assays, and what criteria define high MSI status?

The definitive criteria for high Microsatellite Instability are clear and standardized. In molecular diagnostics, MSI is evaluated by comparing microsatellite allele sizes between a patient’s tumor and normal tissue, looking for novel insertions or deletions that signal a broken DNA mismatch repair (MMR) system. A tumor is classified as MSI-High (MSI-H) when it shows instability in at least two of five reference markers (like BAT25, BAT26, D5S346, D2S123, and D17S250), or, when a larger panel of over five markers is used, when ≥30% of those markers are unstable. This classification directly guides Lynch syndrome screening, prognosis, and chemotherapy decisions.

The core takeaway: MSI evaluation relies on precise amplification and sizing of repetitive DNA sequences, paired with a strict numerical cutoff. You don’t just detect one unstable locus—you look for a systemic pattern of replication errors across a standardized panel, defining MSI-H as instability in ≥20% of NCI-recommended markers or ≥30% of a broader marker set. This pattern, not a single event, is what reveals a clinically actionable MMR deficiency.

How the Evaluation Process Works in a Diagnostic Assay

The Fundamental Comparison: Tumor vs. Normal DNA

The assay always begins with a paired sample: DNA extracted from the patient’s tumor tissue and DNA from a non-tumor source (usually blood or adjacent healthy tissue). This comparison is what rules out benign germline variations. Any size shift seen only in the tumor—but not in the patient’s constitutional DNA—is a potential instability event.

The Molecular Technique: From PCR to Peak Pattern Analysis

The workhorse method is multiplex PCR followed by capillary electrophoresis. Fluorescently labeled primers amplify a selection of microsatellite loci, and the resulting fragments are separated by size with single-base resolution. The assay must reliably distinguish even a one-base-pair insertion or deletion. This demands high-fidelity polymerases and internal size standards to ensure the peaks you see are real slippage errors, not PCR artifacts.

The Panel: Which Loci Are Evaluated?

The National Cancer Institute (NCI) consensus panel is the historical and regulatory anchor. It includes:

• Two mononucleotide repeats (BAT25, BAT26)—preferred for their high sensitivity and quasi-monomorphic nature, meaning they rarely vary in the normal population.
• Three dinucleotide repeats (D5S346, D2S123, D17S250)—which are more polymorphic but still retain utility.

Modern diagnostic assays, especially those built on Next-Generation Sequencing (NGS), often expand the panel to dozens of microsatellites. Yet the principle remains identical: count the fraction of interrogated loci that display a novel allele peak in the tumor.

The Core Criteria That Define MSI-H Status

The Numerical Cutoff: Two of Five, or 30% of All Markers

High MSI is not a spectrum—it’s a binary classification anchored to a threshold of two unstable loci out of the five reference markers. If only one marker (any of the five) shows instability, the result is MSI-Low (MSI-L). If none show instability, the specimen is Microsatellite Stable (MSS).

When a developer moves beyond the five-marker set to a larger panel (for example, 10 or 100 microsatellites), the criterion shifts to a proportional cutoff: instability in ≥30% of the tested loci defines MSI-H. This ensures that the classification reflects a pervasive MMR defect, not just a random high number of false positives from a bigger panel.

Why the Cutoff Matters: Clinical and Assay Implications

The distinction between MSI-H and MSS/MSI-L is clinically actionable. MSI-H status predicts resistance to 5-FU-based adjuvant chemotherapy in colorectal cancer, spares patients unnecessary toxicity, and flags a possible Lynch syndrome diagnosis that requires germline testing. A diagnostic assay that misclassifies a single unstable locus as “unstable enough” would generate false MSI-H calls, leading to incorrect hereditary cancer screening and inappropriate treatment decisions. The cutoff exists to anchor clinical validity.

Common Pitfalls and Trade-offs When Evaluating MSI

The Sensitivity Trap: Mononucleotide vs. Dinucleotide Markers

Assays that rely heavily on dinucleotide repeats can be less sensitive for detecting MMR deficiencies. Dinucleotide loci are naturally more polymorphic, making it harder to distinguish true instability from normal variation without perfect normalization. Many developers now skew their panels toward mononucleotides (like BAT25, BAT26, NR21, NR24) because they provide a cleaner signal. The trade-off is that a purely mononucleotide panel might miss rare MMR defects that selectively affect dinucleotide slippage, so the original NCI blend remains a balanced reference.

The Contamination and Neoplastic Content Problem

Capillary electrophoresis cannot tell you if a low-frequency peak comes from a small unstable subclone or from normal tissue contamination. A tumor sample with a low proportion of neoplastic cells may display a false-normal MSI-L or MSS result because the wild-type peak drowns out the mutant allele. Every laboratory protocol must enforce a specimen adequacy check (e.g., ≥20% tumor nuclei) or risk masking the very instability you’re trying to detect.

Interpreting the Gray Zone: When Percentage Thresholds Fail

Imagine a panel of 12 markers where 3 show instability—that’s 25%, below the 30% cutoff. The result is MSI-L, yet a clinician may still suspect MMR deficiency. This underscores that the cutoff is a statistical consensus for population-level validity, not an absolute biological truth. Assay developers must validate their specific marker set against a gold standard (like MMR immunohistochemistry) to set the threshold that maximizes clinical sensitivity and specificity for that exact combination.

Making the Right Choice for Your Goal

How you apply these criteria depends entirely on what you’re trying to achieve—screening, prognosis, or therapy selection.

• If your primary focus is Lynch syndrome screening: Use a panel anchored by mononucleotide repeat markers and enforce the two-of-five cutoff (or its ≥30% equivalent). Pair the assay with a clear pathway to germline MMR gene testing, because MSI-H is the gateway, not the final diagnosis.
• If your primary focus is therapeutic decision-making in colorectal cancer: Ensure your assay’s absolute accuracy around the MSI-H threshold, because a false MSS call may lead to ineffective 5-FU exposure. Validate your panel’s sensitivity with tumor samples that have confirmed low neoplastic cellularity.
• If your primary focus is developing a new diagnostic product: Start your design with the NCI panel as your regulatory anchor, then add extra mononucleotide markers for robustness. Run a bridging study to demonstrate that your ≥30% cutoff produces equivalent clinical classification to the historical two-of-five standard.

A single unstable peak is noise; a signature of ≥20–30% unstable markers across a thoughtfully chosen panel is the signal of a compromised DNA repair system—and that is the actionable truth every molecular MSI assay must deliver.

Summary Table:

Developing or optimizing molecular diagnostic assays for MSI detection? CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—supporting your pipeline from concept to clinic. Enhance your assay accuracy and high-fidelity PCR performance by contacting us today!